Oppenheimer Reiterates “Outperform” Rating for enGene (NASDAQ:ENGN)

Oppenheimer reissued their outperform rating on shares of enGene (NASDAQ:ENGN) in a research report sent to investors on Tuesday morning, Benzinga reports. Oppenheimer currently has a $30.00 price target on the stock.

Separately, Morgan Stanley restated an overweight rating and set a $40.00 price target on shares of enGene in a report on Wednesday, September 11th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of Buy and a consensus target price of $33.67.

enGene Trading Up 10.0 %

Shares of NASDAQ:ENGN opened at $6.05 on Tuesday. The firm has a fifty day moving average of $7.06 and a two-hundred day moving average of $10.89. The firm has a market capitalization of $267.20 million, a P/E ratio of -3.65 and a beta of -0.68. enGene has a 12-month low of $4.42 and a 12-month high of $43.00. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09.

enGene (NASDAQ:ENGN) last issued its earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. On average, equities analysts expect that enGene will post -1.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Altitude Crest Partners Inc. acquired a new position in enGene during the 1st quarter worth $2,039,000. SR One Capital Management LP acquired a new position in enGene during the 2nd quarter worth $4,715,000. Omega Fund Management LLC acquired a new position in enGene during the 4th quarter worth $10,441,000. Logos Global Management LP lifted its position in enGene by 50.0% during the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after acquiring an additional 400,000 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new position in enGene during the 1st quarter worth $17,095,000. Institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.